ES2147238T3 - Nuevos analogos estructurales de la vitamina d. - Google Patents

Nuevos analogos estructurales de la vitamina d.

Info

Publication number
ES2147238T3
ES2147238T3 ES94924749T ES94924749T ES2147238T3 ES 2147238 T3 ES2147238 T3 ES 2147238T3 ES 94924749 T ES94924749 T ES 94924749T ES 94924749 T ES94924749 T ES 94924749T ES 2147238 T3 ES2147238 T3 ES 2147238T3
Authority
ES
Spain
Prior art keywords
vitamin
ring
analogue
membered
structural analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94924749T
Other languages
English (en)
Inventor
Roger Bouillon
Maurits Vandewalle
Clercq Pierre Jean De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire Theramex SAM
Original Assignee
Laboratoire Theramex SAM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Theramex SAM filed Critical Laboratoire Theramex SAM
Application granted granted Critical
Publication of ES2147238T3 publication Critical patent/ES2147238T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/02—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen
    • C07C47/198—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
    • C07C35/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings
    • C07C35/27—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings the condensed ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/02—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen
    • C07C47/19—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen containing hydroxy groups
    • C07C47/192—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen containing hydroxy groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/28—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
    • C07C47/36—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/28—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
    • C07C47/37—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C07C49/242—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/517—Saturated compounds containing a keto group being part of a ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/687—Unsaturated compounds containing a keto groups being part of a ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/743—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups having unsaturation outside the rings, e.g. humulones, lupulones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/26—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A ANALOGOS DE VITAMINA D, QUE CARECEN DE LA PRESENCIA COMBINADA DEL ANILLO-C DE SEIS ELEMENTOS TRANSFUNDIDO Y DEL ANILLO-D DE CINCO ELEMENTOS, PERO TODAVIA POSEE UNA PARTE CENTRAL QUE CONSISTE EN UNA CADENA SUSTITUIDA DE CINCO ATOMOS, ATOMOS QUE CORRESPONDEN A LAS POSICIONES 8,14,13,17 Y 20 DE VITAMINA D, Y A CUYOS EXTREMOS ESTAN CONECTADOS, EN POSICION 20 UNA UNIDAD ESTRUCTURAL QUE REPRESENTA PARTE DE LA CADENA LATERAL DE VITAMINA D O DE UN ANALOGO DE VITAMINA D, Y EN POSICION 8 LA UNIDAD DELTA/5,7)-DIENO CONECTADA AL ANILLO-A DEL METABOLITO 1-ALFA-HIDROXI O DE UN ANALOGO ESTABLECIDO DE VITAMINA D, A SU PROCESO DE PREPARACION, A INTERMEDIO DE PREPARACION, O PREPARACIONES FARMACEUTICAS QUE COMPRENDEN ESTOS COMPUESTOS Y A SU USO EN MEDICINA.
ES94924749T 1993-07-09 1994-07-07 Nuevos analogos estructurales de la vitamina d. Expired - Lifetime ES2147238T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93202037 1993-07-09

Publications (1)

Publication Number Publication Date
ES2147238T3 true ES2147238T3 (es) 2000-09-01

Family

ID=8213977

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94924749T Expired - Lifetime ES2147238T3 (es) 1993-07-09 1994-07-07 Nuevos analogos estructurales de la vitamina d.
ES99203513T Expired - Lifetime ES2209327T3 (es) 1993-07-09 1994-07-07 Nuevos analogos estructurales de la vitamina d.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99203513T Expired - Lifetime ES2209327T3 (es) 1993-07-09 1994-07-07 Nuevos analogos estructurales de la vitamina d.

Country Status (16)

Country Link
US (2) US6017907A (es)
EP (2) EP0707566B1 (es)
JP (2) JP4235256B2 (es)
CN (1) CN1103755C (es)
AT (2) ATE251133T1 (es)
AU (1) AU699200B2 (es)
CA (1) CA2166898C (es)
DE (2) DE69423966T2 (es)
DK (2) DK0707566T3 (es)
ES (2) ES2147238T3 (es)
GR (1) GR3033856T3 (es)
NO (1) NO314142B1 (es)
NZ (1) NZ271332A (es)
PT (2) PT707566E (es)
RU (1) RU2153491C2 (es)
WO (1) WO1995001960A1 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4235256B2 (ja) * 1993-07-09 2009-03-11 カー・イュー・ルーベン・リサーチ・アンド・ディベロップメント 新規ビタミンｄ構造類似体
BR9509739A (pt) * 1994-11-21 1997-10-21 Wisconsin Alumni Res Found Compostos 18,19-dinor-vitamina d
US5661140A (en) * 1994-11-21 1997-08-26 Wisconsin Alumni Research Foundation 18-nor-vitamin D compounds
DE69606680T2 (de) * 1995-10-30 2000-08-17 F. Hoffmann-La Roche Ag, Basel 1-Alpha, 26-dihydroxy-D-homo-vitamin D3
CN1201452A (zh) * 1995-10-31 1998-12-09 弗·哈夫曼-拉罗切有限公司 24－高－26,27－六氟－胆钙化甾醇
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
DE19619036A1 (de) 1996-04-30 1997-11-13 Schering Ag Neue Vitamin D-Derivate mit carbo- oder heterocyclischen Substituenten an C-25, Verfahren zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
EP0983221B1 (en) * 1997-05-23 2002-04-03 Basilea Pharmaceutica AG Cyclohexanediol derivatives
AU735676B2 (en) * 1997-06-10 2001-07-12 Mrc Holdings Pty Limited Method of treatment of liver tumours and pharmaceutical compositions for use therein
AUPO727097A0 (en) 1997-06-10 1997-07-03 Unisearch Limited Method of treatment of hepatoma and pharmaceutical compositions for use therein
JP4219553B2 (ja) 1997-09-08 2009-02-04 エフ．ホフマン−ラ ロシュ アーゲー １，３−ジヒドロキシ−２０，２０−ジアルキル−ビタミンｄ３類似体
US5919986A (en) * 1997-10-17 1999-07-06 Hoffmann-La Roche Inc. D-homo vitamin D3 derivatives
WO1999043645A1 (en) * 1998-02-24 1999-09-02 Chugai Seiyaku Kabushiki Kaisha 24-hydroxyvitamin d derivatives
US6184422B1 (en) * 1998-02-26 2001-02-06 Hoffman-La Roche Inc. Cyclohexanediol derivatives
EP2340840B1 (en) * 1998-03-27 2012-08-29 Oregon Health Sciences University Pulse dose Vitamin D drug for the treatment of hyperproliferative skin diseases
US5962707A (en) * 1998-08-18 1999-10-05 Wisconsin Alumni Research Foundation 19-nor-vitamin D3 compounds with calcemic activity
US6479474B2 (en) 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
DE19935771A1 (de) 1999-07-23 2001-02-01 Schering Ag Neue Vitamin D-Derivate mit cyclischen Substrukturen in den Seitenketten, Verfahren und Zwischenprodukte zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
US6310262B1 (en) * 1999-10-18 2001-10-30 Basilea Pharmaceutica Ag Process for preparing retiferol derivatives
KR100732271B1 (ko) 1999-12-08 2007-06-25 라보라뚜와르 떼라멕스 비타민 디 전구체, 제조방법 및 중간체
EP1106618A1 (en) * 1999-12-08 2001-06-13 Laboratoire Theramex Precursors of the A-ring of vitamin D, and method and intermediates for the preparation thereof
US7632518B2 (en) * 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
GB0305332D0 (en) * 2003-03-10 2003-04-09 Leuven K U Res & Dev Biological evaluation of novel vitamin D analogues
AU2004247108A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc Treatment of immune-mediated disorders with active vitamin D compounds alone or in combination with other therapeutic agents
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
GB0422929D0 (en) * 2004-10-15 2004-11-17 Leuven K U Res & Dev Bioactive vitamin D analogues
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
GB0423091D0 (en) * 2004-10-19 2004-11-17 Leuven K U Res & Dev Bioactive vitamin d analogues
US20080069814A1 (en) * 2005-01-05 2008-03-20 Novacea, Inc. Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof
MX2007013029A (es) * 2005-04-22 2008-01-11 Novacea Inc Tratamiento, prevencion y mejora de trastornos pulmonares asociados con la quimioterapia o radioterapia con compuestos activos de vitamina d o substancias mimeticas de los mismos.
EP2247563A1 (en) * 2008-01-22 2010-11-10 Wisconsin Alumni Research Foundation 13,13-dimethyl-des-c,d analogs of 1alpha, 25-dihydroxy-19-nor-vitamin d3 compounds and topical composition dosage forms and methods of treating skin conditions thereof
US8109466B2 (en) * 2008-06-23 2012-02-07 Rohr, Inc. Thrust reverser cascade assembly and AFT cascade ring with flow deflector portion
CA2750659C (en) 2009-01-27 2017-11-21 Berg Biosystems, Llc Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
MX2011012330A (es) * 2009-05-20 2011-12-16 Hybrigenics Sa Nuevos usos terapeuticos de inecalcitol.
EA201270226A1 (ru) 2009-08-14 2012-09-28 БЕРГ БАЙОСИСТЕМЗ, ЭлЭлСи Витамин d3 и его аналогии для лечения алопеции
PL2360145T3 (pl) * 2010-01-26 2012-08-31 Hybrigenics Sa Nowy sposób izomeryzacji skondensowanych struktur bicyklicznych oraz wytwarzania zawierających te struktury analogów witaminy D
ES2795849T3 (es) * 2010-05-20 2020-11-25 Hoffmann La Roche Reactivo de liberación para compuestos de vitamina D
EP2407152A1 (en) 2010-07-15 2012-01-18 Hybrigenics S.A. Formulations of 14-epi-analogues of vitamin D
US20120015913A1 (en) 2010-07-15 2012-01-19 Delansorne Remi Formulations of 14-EPI-Analogues of Vitamin D
EP2407155B1 (en) 2010-07-15 2012-12-26 Hybrigenics S.A. Formulations of inecalcitol
KR102108582B1 (ko) 2011-11-18 2020-05-08 에프. 호프만-라 로슈 아게 비타민 d 화합물용 방출 시약
EP2785687B1 (en) 2011-11-30 2019-02-20 Sandoz AG Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
CN104024237B (zh) 2011-12-16 2016-02-24 阿方拉研究股份有限公司 用于制备3-((2s,5s)-4-亚甲基-5-(3-氧代丙基)四氢呋喃-2-基)丙醇衍生物的方法及其有用的中间体
US9062020B2 (en) 2011-12-29 2015-06-23 Alphora Research Inc. 2-((2S,3S,4R,5R)-5-((S)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
EP2831082B1 (en) 2012-03-30 2019-02-20 Sandoz AG Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
MX2015012111A (es) 2013-03-14 2016-05-05 Aquinox Pharmaceuticals Canada Inc Moduladores de ship1 y métodos relacionados con éstos.
MX2015011280A (es) 2013-03-14 2016-03-03 Aquinox Pharmaceuticals Canada Inc Moduladores de ship1 y metodos relacionados con los mismos.
HK1222819A1 (zh) 2013-05-29 2017-07-14 博格有限责任公司 使用维生素d预防或减轻化疗诱发的脱发
GB2515128B (en) 2013-06-10 2015-05-27 Givaudan Sa Improvements in or relating to organic compounds
EP3094615A4 (en) 2014-01-13 2017-11-08 P2 Science, Inc. Terpene-derived acids and esters and methods for preparing and using same
WO2015196019A1 (en) 2014-06-20 2015-12-23 P2 Science, Inc. Film ozonolysis in a tubular or multitubular reactor
EP3177587A4 (en) * 2014-08-06 2018-01-17 P2 Science, Inc. Fragrances from the esters of fatty acids
GB201421855D0 (en) * 2014-12-09 2015-01-21 Givaudan Sa Improvements in or relating to organic compounds
WO2016210146A1 (en) 2015-06-26 2016-12-29 Aquinox Pharmaceuticals (Canada) Inc. Crystalline solid forms of the acetate salt of (1s,3s,4r)-4-((3as,4r,5s,7as)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1h-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol
AU2017209430A1 (en) 2016-01-20 2018-07-12 Aquinox Pharmaceuticals (Canada) Inc. Synthesis of a substituted indene derivative
US10668446B2 (en) 2016-06-21 2020-06-02 P2 Science, Inc. Flow-through reactors for the continuous quenching of peroxide mixtures and methods comprising the same
EP3512631B1 (en) 2016-09-16 2022-03-23 P2 Science, Inc. Uses of vanadium to oxidize aldehydes and ozonides
JP7546296B2 (ja) 2018-10-19 2024-09-06 ピー２・サイエンス・インコーポレイテッド オゾニドの不均化クエンチの新規方法
CN110330522A (zh) * 2019-07-29 2019-10-15 南京海融医药科技股份有限公司 一种帕立骨化醇异构体杂质py5的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3590020T1 (de) * 1984-01-30 1986-01-23 Wisconsin Alumni Research Foundation, Madison, Wis. In der Seitenkette ungesättigte 1-Hydroxyvitamin D-Verbindungen
NZ232734A (en) * 1989-03-09 1991-11-26 Wisconsin Alumni Res Found 19-nor vitamin d derivatives and pharmaceutical compositions
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
DE3913310A1 (de) * 1989-04-20 1990-10-25 Schering Ag Spirocyclopropane in der vitamin d-reihe
AU650751B2 (en) * 1991-05-28 1994-06-30 Wisconsin Alumni Research Foundation Novel synthesis of 19-nor vitamin D compounds
AU666563B2 (en) * 1992-08-07 1996-02-15 Wisconsin Alumni Research Foundation Preparation of 19-nor-vitamin D compounds
IL107185A (en) * 1992-10-06 1998-02-22 Schering Ag Vitamin d, 25-carboxylic acid derivatives and pharmaceutical compositions containing the same
JP4235256B2 (ja) * 1993-07-09 2009-03-11 カー・イュー・ルーベン・リサーチ・アンド・ディベロップメント 新規ビタミンｄ構造類似体

Also Published As

Publication number Publication date
DK0707566T3 (da) 2000-09-04
NO960099D0 (no) 1996-01-09
US6017907A (en) 2000-01-25
NO314142B1 (no) 2003-02-03
WO1995001960A1 (en) 1995-01-19
DE69423966T2 (de) 2000-11-16
NO960099L (no) 1996-03-08
EP0972762A2 (en) 2000-01-19
DK0972762T3 (da) 2004-02-09
NZ271332A (en) 2001-03-30
ATE251133T1 (de) 2003-10-15
JP2006001944A (ja) 2006-01-05
GR3033856T3 (en) 2000-10-31
ES2209327T3 (es) 2004-06-16
EP0972762B1 (en) 2003-10-01
CA2166898C (en) 2004-09-07
ATE191712T1 (de) 2000-04-15
PT972762E (pt) 2004-02-27
DE69433220T2 (de) 2004-08-19
RU2153491C2 (ru) 2000-07-27
JP4312183B2 (ja) 2009-08-12
JP4235256B2 (ja) 2009-03-11
AU699200B2 (en) 1998-11-26
EP0972762A3 (en) 2000-02-23
CA2166898A1 (en) 1995-01-19
PT707566E (pt) 2000-09-29
US6548715B1 (en) 2003-04-15
CN1130899A (zh) 1996-09-11
EP0707566B1 (en) 2000-04-12
AU7492794A (en) 1995-02-06
EP0707566A1 (en) 1996-04-24
JPH09500117A (ja) 1997-01-07
DE69423966D1 (de) 2000-05-18
CN1103755C (zh) 2003-03-26
DE69433220D1 (de) 2003-11-06

Similar Documents

Publication Publication Date Title
ES2147238T3 (es) Nuevos analogos estructurales de la vitamina d.
ES2070628T3 (es) Uso de compuestos analogos a 1,3-oxatiolano-nucleosidos en la fabricacion de un medicamento para el tratamiento de la hepatitis b.
DE59102210D1 (de) Galanthemin enthaltende pharmazeutische Formulierung zur Behandlung des Alkoholismus.
ITMI920528A1 (it) 14-beta idrossi-10-deacetil-baccatina iii, suoi derivati, loro prepazione ed impiego terapeutico
NO172389C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzotiazoler
ZA928170B (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of alpha-D-neuraminic acid
ES2093440T3 (es) Derivados en la serie de la vitamina d con modificaciones en la posicion 20, procedimiento para su preparacion, productos intermedios para este procedimiento, preparados farmaceuticos que contienen estos derivados asi como su utilizacion para la preparacion de medicamentos.
DK515489A (da) Dispergerbar laegemiddelformulering
GR900100644A (en) Derma atropho glycocorticoids leversal
DK0384842T3 (da) 19-nor-steroider substitueret i 11beta-stillingen med en carbonkæde med en amid- eller carbamatgruppe, deres fremstillingsmetode og mellemprodukter med denne fremstillingsmetode, deres anvendelse som lægemidler og farmaceutiske præparater med indhold deraf
SE8704952D0 (sv) Farmaceutisk komposition
IT8721691A0 (it) Derivati dell'ossima della 1,2,5,6-tetraidropirdin-3-carbossaldeide, loro procedimento di preparazione e loro impiegocome sostanze medicinali.
IT8721687A0 (it) Derivati dell'ossima della 1,2,5,6-tetraidropiridin-3-carbossa ldeide, loro procedimento di preparazione e loro impiego come sostanze medicinali.
EP0272596A3 (en) Theophyllinemethyldithiolan and theophyllinemethyldithianyl derivates, a method for their preparation and pharmaceutical compositions in which they are included
NO172491C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksan-alkensyre-dervater
IT1228130B (it) Derivati dell'1,1,2-trifenilpropano e dell'1,1,2-trifenilpropene, procedimento per la loro preparazione e composizioni farmaceutiche contenenti i composti
MX9303392A (es) Derivados de imidazo benzoxazin-1-ona substituidos y proceso para su preparacion.
LU81501A1 (fr) Compositions pharmaceutiques comprenant de la trimethoprime,ainsi que des derives d'acides n-ethyl-gamma-pyridone-3-carboxyliques
ITMI911845A1 (it) Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
ITMI911841A1 (it) Derivati dell'eseridina utili per il trattamento delle malattie associaate a disordini colinergici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
ITMI912027A1 (it) Derivati dell'eserolina utili per il trattamento delle malattie associate a disordini colinergici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
ITMI911842A1 (it) Derivati dell'eseridina utili per il trattamento delle malattie associate a disordini colinergici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
ITMI911713A1 (it) Derivati dell'eseridina utili per il trattamento delle malattie associate a disordini colinergici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
ITMI911758A1 (it) Derivati della fisovenina utili per il trattamento delle malattie associate a disordini colinergici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
IT1245390B (it) Composizione farmaceutica ad attivita' antivirale

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 707566

Country of ref document: ES